Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | JAKARTA 1 & 2: response rapidity & durability

Ruben Mesa • 8 Jun 2020
EHA 2020
Myelofibrosis Fedratinib
JAKARTA JAKARTA2

Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the rapidity and durability of response, in the JAKARTA1 (NCT01437787) and JAKARTA2 (NCT01523171) studies evaluating fedratinib in patients with intermediate or high-risk myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ruben Mesa

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
How meaningful benefit in MPNs could evolve over the next five years
2:04
How meaningful benefit in MPNs could evolve over the next five years
Ruben Mesa • 2 Oct 2026
Insights into the evolving treatment landscape for MPNs: current state and future directions
2:22
Insights into the evolving treatment landscape for MPNs: current state and future directions
Ruben Mesa • 12 Jun 2026

Related Videos

When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026
Emerging therapeutic strategies and future directions in MPNs
3:00
Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova • 4 Oct 2026
MPN Progression Registry: insights into the work of the MPN Research Foundation
19:15
MPN Progression Registry: insights into the work of the MPN Research Foundation
David Shoultz et al. • 2 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals